Abstract
Last years, prostate cancer PET imaging was marked by the rise of the use of radiolabelled PSMA ligands. This recent imaging modality demonstrated a tremendous impact on the diagnostic and patient disease management, from initial staging to castration-resistant prostate cancer. The purpose of this article is to highlight data of interest published in 2020 related to the main radiolabelled PSMA ligands that are use for prostate cancer PET/CT imaging, and to discuss pending issues.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
